pharmaceutical

Pfizer's 6.4% dividend yield attracts income investors, but structural challenges like patent expirations and a payout ratio exceeding 100% present execution risks.

Aquestive Therapeutics will report Q4 2025 results March 4 and hold investor call March 5, discussing financial performance and pipeline progress including Anaphylm™ development.

Veeva Systems targets $6B revenue by 2030, doubling current business. Stock down 35% recently, but specialized platform and customer switching costs support long-term growth outlook.

Takeda stock fell 0.64% despite positive Phase 3 results for Entyvio in pediatric ulcerative colitis, with 47.3% of patients achieving clinical remission.

Nasus Pharma CEO presents clinical pipeline at three major healthcare conferences in February-March, showcasing NS002 intranasal epinephrine for anaphylaxis treatment.

AbbVie stock fell despite strong Q4 results and 10% revenue growth. Investors worry about Humira patent expiration, though new drugs Skyrizi and Rinvoq show promise.